Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

Acute Effects of TENS on Cervical Muscle Stiffness and Pain in Neck Pain

NCT07244861 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-09-23
Last updated
2025-11-24

Condition(s) studied

Neck PainChronic Neck PainMuscle StiffnessTranscutaneous Electrical Nerve Stimulation

Investigational drug(s) / intervention(s)

Transcutaneous Electrical Nerve StimulationSham TENS

Transcutaneous Electrical Nerve Stimulation: Conventional mode TENS, frequency \~80 Hz, pulse width ≤150 µs, duration 20 minutes. Intensity set to "strong but tolerable" without visible muscle contraction. Electrodes placed bilaterally over the most painful/stiff segments (e.g., upper trapezius midpoint along C7-acromion line; adjustments per comfort

Sham TENS: Electrodes applied at the same anatomical sites as the active arm. Device indicators remain on; intensity is ramped to perception briefly and then reduced to sub-sensory/zero so that no effective current is delivered for the remainder of the 20-minute session. Procedures and clinician-participant interactions mirror the active arm

Study summary

This randomized controlled trial investigates the acute effects of transcutaneous electrical nerve stimulation (TENS) on passive cervical muscle stiffness (MyotonPro "dynamic stiffness", N/m) and pain (0-10 VAS) in adults with chronic/mechanical neck pain. Participants will be allocated 1:1 to TENS or control/sham. Outcomes are measured immediately before and immediately after a single 15-minute session.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18-50 years. Neck pain VAS ≥ 3/10 at screening and on test day. Clinical diagnosis of chronic or mechanical neck pain (≥6 weeks). Able to understand study procedures and provide written informed consent. Willing to refrain from analgesics/muscle relaxants and vigorous neck/shoulder exercise for 24 hours before testing. Exclusion Criteria: * Cervical radiculopathy or neurological signs (myotomal weakness, dermatomal sensory loss, reflex changes). Recent invasive procedures to the neck/shoulder (e.g., surgery, injections, radiofrequency/neurotomy) within 6 weeks. Pacemaker/implantable cardioverter, or other active implanted electronic device. Pregnancy or planning pregnancy. Skin conditions at electrode sites (open wounds, infection, severe dermatitis) or known allergy to electrode adhesive/gel. History of epilepsy or unexplained syncope. Acute neck trauma (\<6 weeks) or red flags (fracture, malignancy, infection, inflammatory rheumatic disease). Systemic disorders likely to affect outcomes (e.g., uncontrolled diabetes with neuropathy, severe cardiovascular disease, fibromyalgia with widespread pain). Ongoing electrotherapy to the neck region or botulinum toxin injections to cervical muscles within 3 months. Inability to comply with procedures (e.g., severe communication/cognitive impairment), or insufficient proficiency in Turkish to complete measures.

Primary outcome measure(s)

  • Change in upper trapezius dynamic stiffness — Pre-session (T0) and immediately post-session (T1; within 5 minutes of session end)
    Passive muscle dynamic stiffness (N/m) measured with MyotonPro at a standardized landmark on the upper trapezius (midpoint along the C7-acromion line; side = most symptomatic or bilateral mean).

Trial sites (1)

FacilityCityRegionStatus
Erzurum Technical University Faculty of Health Sciences Erzurum Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07244861 on ClinicalTrials.gov ↗ ← All trials in Turkey